Medicamen Organics LtdQ1 FY25Pharmaceuticals & Biotechnology

Medicamen Organics Ltd

Q1 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 1

→Medicamen Organics targets revenues of INR 60-65 crores for FY '26.
→The company plans a 60% CAGR in revenue over the next three years.
→Expansion includes a 20% capacity increase at the Haridwar facility.
→Nepal facility expected to contribute from FY '27 onwards, with optimum potential above INR 400 crores.
→Focus on growing export markets, aiming for 75% export and 25% domestic revenue mix.
→Plans to register around 120 products in Africa over the next two years.
→Growth driven by diversification into personal care/cosmetics with INR 15 crores revenue targeted for FY '26.
→Expansion into better, more profitable markets like Latin America and Europe through associate manufacturing.
→Anticipated rise in volumes supported by capacity additions and geographic market expansion.

Category 3

→Medicamen Organics Limited targets **60% CAGR revenue growth** over the next three years.
→For FY '26, projected revenue is around **INR 60-65 crores**.
→EBITDA margins expected around **24%**, considering new segments like cosmetics and personal care.
→Profit After Tax (PAT) aims to be maintained at or above **10%**.
→Growth drivers include expansion into new markets such as East Africa, Nepal, and Europe, with 120 product registrations planned.
→Margins are currently around 17%, expected to improve as marketing investments stabilize and focus shifts to profitable products.
→Optimum utilization of existing capacity is 60-65%, with a planned **20% capacity expansion** to support growth.
→Nepal facility to contribute significantly after commercialization, with potential revenues exceeding **INR 400 crores** at full optimal utilization.
→EPS expected to improve in line with revenue and profitability growth, supported by internal accrual funding and no immediate dividend payout to reinvest in expansion.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Medicamen Organics Ltd and 1,400+ other companies.

→Currently, Medicamen Organics Limited is funding all its expansion through internal accruals.
→There are no immediate plans for generating funds through debt or equity.
→The company has raised INR 3 crores via issuing and allotting 4,65,910 convertible warrants on a preferential basis to the Promoter Group to strengthen working capital without affecting the existing financial structure.
→For the Nepal facility investment, the company plans to invest around INR 9 crores as its portion of capital, which will be funded internally.
→No explicit mention of future fundraising through debt or equity was made; the focus remains on internal accrual funding and controlled investments.

→Current orders in hand with the East Africa subsidiary stand at around $125,000.
→An advance payment of $50,000 has been received from the subsidiary.
→The first shipment from the East Africa operations is scheduled for this month.
→Post initial shipment, similar subsequent orders are expected.
→The company is preparing for a good influx of orders this year, supported by 20% capacity expansion at the primary facility.
→Focus on markets like Latin America (Mexico, Brazil), Europe, and Francophone Africa is expected to drive order growth.
→The company is also targeting registrations of around 120 products over the next two years, which should contribute significantly to revenues from FY '26 onwards.

Yes

→INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited.
→Expansion of Haridwar manufacturing facility by 20% underway to enhance operational efficiency and scale production.
→Plans to construct an EU-approved manufacturing facility for better control over production, targeted commercialization starting around 15 months from now, with first-year revenue potential of INR50 crores.
→No current plans for fundraising; expansions funded through internal accruals and INR3 crores raised via convertible warrants from Promoter Group.
→The Nepal facility represents a strategic investment to enter new markets and meet European quality standards, supplementing capacity and global footprint.
→Future plan includes possible manufacturing facility in Africa in 2-3 years to access new markets.

How does Medicamen Organics Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Medicamen Organics Ltd

Rev 1Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Medicamen Organics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.